@booklet {892316,
	title = {Multidrug-Resistant Tuberculosis Treatment in Peru},
	journal = {Harvard Business Publishing},
	year = {2011},
	abstract = {
	This case traces the development of a multidrug-resistant tuberculosis (MDR-TB) treatment program in Peru between 1994 and 1999 by Socios en Salud (SES), a community-based nonprofit organization, in a shantytown of Northern Lima called Carabayllo. After providing some background on existing TB treatment services and the organizational history of SES, it follows the organization up to 1999 and frames its work within the context of international MDR-TB policy. The case presents background information on the epidemiology of TB and MDR-TB in Peru as well as the shantytown of Carabayllo. It describes how SES implemented community-based treatment for cadre of patients with MDR-TB and achieved cure rates comparable with those obtained in the US. The case begins with a vignette that illuminates the problem of MDR-TB from a patient{\textquoteright}s perspective and ends with the program needing to strategize about how to scale-up and expand its reach to more patients.



	Teaching Note\&nbsp;available through Harvard Business Publishing.



	[[{"fid":"3308516","view_mode":"default","type":"media","attributes":{"height":"480","width":"360","alt":"Outdoor sputum collection booth to prevent TB transmission in (MOH) national hospital in northern shantytown of Peru","title":"Outdoor sputum collection booth to prevent TB transmission in (MOH) national hospital in northern shantytown of Peru","class":"media-element file-default"}}]]Outdoor sputum collection booth to prevent TB transmission in (MOH) national hospital in northern shantytown of Peru; Credit: Julie Rosenberg Talbot



	Learning Objectives:\&nbsp;To understand strategies that innovative programs use to improve access to health care and to explore ways that community health workers can deliver complex medical interventions within well-designed public health programs.



	Keywords:\&nbsp;Community health workers, multi-drug resistant tuberculosis treatment, policy change, advocacy

},
	author = {Julie Rosenberg and Joseph Rhatigan}
}
